<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01274702</url>
  </required_header>
  <id_info>
    <org_study_id>Vision Study</org_study_id>
    <nct_id>NCT01274702</nct_id>
  </id_info>
  <brief_title>Visual Reconstitution Therapy After Optic Neuritis</brief_title>
  <acronym>VISION</acronym>
  <official_title>Visual Reconstitution Therapy After Optic Neuritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beuth Hochschule für Technik Berlin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NovaVision AG, Zentrum für Sehtherapie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Incomplete remission after an optic neuritis attack is not uncommon. Visual reconstitution
      therapy is a software-based approach that has been shown to substantially improve residual
      visual field deficits in patients with pre- and postchiasmatic lesions.

      The primary hypothesis of this randomized, controlled clinical trial is, that visual
      reconstitution therapy is superior to active comparator treatment in improving the visual
      field after optic neuritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with an acute optic neuritis (between 60 and 180 days before screening) or with
      residual visual deficits after a past optic neuritis are randomized in two treatment groups.
      Group A is instructed to perform software-based visual reconstitution therapy on a home PC
      daily and regularly for 30 minutes over a period of six month. Group B will perform a
      similarly, also software-based training program, developed to improve saccadic eye movements
      rather than visual fields. Patients are blinded to the respective treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual field</measure>
    <time_frame>6 months</time_frame>
    <description>visual field perimetry and kampimetry at baseline and after 3 and 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>structural retinal changes</measure>
    <time_frame>6 months</time_frame>
    <description>Optical coherence Tomography is performe at baselline and after 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>6 months</time_frame>
    <description>Quality of life is determined by questionaires at baseline and after 6 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Optic Neuritis</condition>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Visual Reconstitution Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saccadic Eye Movement Training</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Visual Reconstitutions Therapy</intervention_name>
    <arm_group_label>Visual Reconstitution Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saccadic Eye Movement Training</intervention_name>
    <arm_group_label>Saccadic Eye Movement Training</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Definite Optic Neuritis within 60-180 Days or &lt; 12 months before Screening

          -  Visus &gt; 0.05

          -  Visus &lt; 0.7 or confirmed visual field deficit

          -  Ability to give Informed Consent

        Exclusion Criteria:

          -  Systemic Treatment with Glucocorticosteroids within 30 days prior to Screening

          -  Additional significant ophthalmological disease

          -  Pregnancy

          -  History of Epilepsy

          -  Significant arterial Hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Friedemann Paul, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NeuroCure Clinical Research Center, Charité Universitaetsmedizin Berlin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NeuroCure Clinical Reserach Center, Charité Universitaetsmedizin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2011</study_first_submitted>
  <study_first_submitted_qc>January 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2011</study_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <responsible_party>
    <name_title>Friedemann Paul</name_title>
    <organization>Charité Universitaetsmedizin Berlin, Germany</organization>
  </responsible_party>
  <keyword>History of</keyword>
  <keyword>Patients</keyword>
  <keyword>acute</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Neuritis</mesh_term>
    <mesh_term>Optic Neuritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

